The Next Chapter for $HIMS

In partnership with

Missed OpenAI? The Clock Is Ticking on RAD Intel’s Round

Ground floor opportunity on predictive AI for ROI-based content.

RAD Intel is already trusted by a who’s-who of Fortune 1000 brands and leading global agencies with recurring seven-figure partnerships in place.

$50M+ raised. 10,000+ investors. Valuation up 4,900% in four years*.

Backed by Adobe and insiders from Google. Shares at $0.81 until Nov 20 — then the price moves. Invest now.

Lock $0.81 Shares Before 11/20

_{This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.}

Hims & Hers Health $HIMS ( ▼ 1.89% ) just reported another quarter of impressive top-line expansion. The telehealth platform delivered $599 million in Q3 revenue, up 49% year over year, beating expectations by nearly $20 million. GAAP EPS came in at $0.06, missing estimates by $0.04, but management’s tone on the call remained firmly optimistic.

The company also dropped some very bullish news: talks with Novo Nordisk $NVO ( ▲ 1.36% ) are back on for a potential partnership around the upcoming oral version of Wegovy — the blockbuster GLP-1 weight loss drug.

With the FDA decision date set for later this quarter, Hims could soon become one of the first telehealth distributors of an approved oral GLP-1 treatment. For us investors, that’s a significant narrative shift — not just a weight-loss play, but a platform that’s becoming increasingly embedded in personalized, long-term healthcare.

Despite the strong results and upbeat guidance, HIMS shares fell nearly 10% last week, mostly due to overall market weakness as the growth-heavy Nasdaq Composite Index tumbled more than 3%.

This seems like a fresh opportunity for long-term investors to scoop up shares of this high-growth telehealth player. Let’s dive a little deeper into the most recent results.

🤝Support Our Caffeinated Community